T6325

PCI-34051 is an effective and selective HDAC8 inhibitor (IC50: 10 nM).

β-Glucuronidase-IN-2 is a potent inhibitor of E. coli β-glucuronidase [IC50: 0.24 μM, Ki: 1.09 μM] and exhibits anti-proliferative effects with potential for anti-cancer and anti-inflammatory therapeutic studies.

Riodoxol is an antiviral agent that effectively affects the reproduction and maturation of viruses.

Antibacterial agent 113 was an effective antimicrobial agent (antibacterial) against P. aeruginosa, S. mutans, B. subtilis, E. coli, E. faecalis, S. typhimuriumand and S. aureus microorganisms exhibited antibacterial effects with MIC values of 15625 μM.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

BTK-IN-11 is a potent BTK inhibitor with potential applications in research on autoimmune diseases, inflammatory diseases, and cancer.

PD-1-IN-17 TFA is a potent inhibitor of programmed cell death-1 (PD-1), effectively inhibiting 92% of splenocyte proliferation at a concentration of 100 nM.

Bucladesine calcium (Dibutyryl cAMP calcium salt) is a cell-permeable cAMP analog and selective PKA activator that increases intracellular cAMP levels. Bucladesine calcium also functions as a phosphodiesterase (PDE) inhibitor with anti-inflammatory activity.

NI-Pano (CH-03) is a novel hypoxia-activated KDAC inhibitor that enables O2-dependent release of panobinostat.

PP2A Cancerous-IN-1 is a potent inhibitor of CIP2A (Cancerous inhibitor of PP2A) and p-Akt, demonstrating significant anti-proliferative effects.